NCT03386357 2026-03-12
Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
University of Erlangen-Nürnberg Medical School
Phase 2 Terminated
Clinical Trials
124 trialsNCT05926960 2026-03-09
PORTSIDE
Pfizer
Phase 2 Terminated
NCT03514017 2026-03-02
Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT04268277 2026-02-27
Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY
University of Ulm
Phase 2 Terminated
NCT03990961 2026-02-20
Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)
University of Chicago
Phase 2 Terminated
NCT06682806 2026-02-02
A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Prelude Therapeutics
Phase 2 Terminated
NCT05814666 2026-01-30
PEMDA-HN
Flamingo Therapeutics NV
Phase 2 Terminated
NCT04095689 2026-01-23
INTEGRAL
The Methodist Hospital Research Institute
Phase 2 Terminated
NCT04862455 2026-01-23
NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT06006923 2026-01-20
Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer
University of Pittsburgh
Phase 2 Terminated
NCT03844750 2025-12-31
Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases
University of California, San Francisco
Phase 2 Terminated
NCT04601857 2025-12-31
Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma
Taiho Oncology, Inc.
Phase 2 Terminated
NCT04986852 2025-12-30
Olinvacimab With Pembrolizumab in Patients With mTNBC
PharmAbcine
Phase 2 Terminated
NCT05141357 2025-12-24
HBI-8000
HUYABIO International, LLC.
Phase 2 Terminated
NCT05179603 2025-12-24
A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]
Sanofi
Phase 2 Terminated
NCT03225547 2025-12-23
Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer
University of Chicago
Phase 2 Terminated
NCT05998447 2025-12-16
GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer
Genome & Company
Phase 2 Terminated
NCT03595683 2025-12-08
Pembrolizumab and EDP1503 in Advanced Melanoma
University of Chicago
Phase 2 Terminated
NCT04955743 2025-11-24
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
Yale University
Phase 2 Terminated
NCT04370509 2025-11-19
Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery
University of California, San Francisco
Phase 2 Terminated
NCT04854499 2025-11-19
ELEVATE HNSCC
Gilead Sciences
Phase 2 Terminated
NCT05256381 2025-11-17
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
Sotio Biotech Inc.
Phase 2 Terminated
NCT04003610 2025-11-04
Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)
Incyte Corporation
Phase 2 Terminated
NCT04964960 2025-10-31
Pembro+Chemo in Brain Mets
University of Kentucky
Phase 2 Terminated
NCT04524689 2025-10-29
CARMEN-LC05
Sanofi
Phase 2 Terminated
NCT06046482 2025-10-22
Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05846646 2025-10-20
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC
ImmuneSensor Therapeutics Inc.
Phase 2 Terminated
NCT04914897 2025-10-02
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)
Sanofi
Phase 2 Terminated
NCT05263492 2025-10-02
Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer
Virginia Commonwealth University
Phase 2 Terminated
NCT05061420 2025-09-22
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)
Sanofi
Phase 2 Terminated
NCT03108495 2025-09-17
Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma
Iovance Biotherapeutics, Inc.
Phase 2 Terminated
NCT05036681 2025-09-17
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03347617 2025-09-09
Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT03018288 2025-08-08
Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT04581824 2025-08-08
Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
GlaxoSmithKline
Phase 2 Terminated
NCT05980598 2025-08-01
BelieveIT-201
Ascendis Pharma A/S
Phase 2 Terminated
NCT05617313 2025-07-30
Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer
Grid Therapeutics
Phase 2 Terminated
NCT02892201 2025-07-29
Pembrolizumab in HNSCC With Residual Disease After Radiation
Yale University
Phase 2 Terminated
NCT05691829 2025-07-29
IRRADIATE-Lung
NYU Langone Health
Phase 2 Terminated
NCT04729348 2025-07-25
Pembrolizumab And Lenvatinib In Leptomeningeal Metastases
Massachusetts General Hospital
Phase 2 Terminated
NCT03401853 2025-07-22
Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma
University of Washington
Phase 2 Terminated
NCT05059470 2025-07-08
IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05634577 2025-06-19
A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04830124 2025-06-10
ARTISTRY-6
Mural Oncology, Inc
Phase 2 Terminated
NCT04394624 2025-06-06
CARMEN-LC04
Sanofi
Phase 2 Terminated
NCT06140407 2025-06-05
Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT04251169 2025-06-03
TATEN
SOLTI Breast Cancer Research Group
Phase 2 Terminated
NCT04849364 2025-05-31
PERSEVERE
Hoosier Cancer Research Network
Phase 2 Terminated
NCT04171219 2025-05-16
Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04633278 2025-05-11
CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Regeneron Pharmaceuticals
Phase 2 Terminated